https://www.thebodypro.com/author/myles-helfand

Latest by Myles Helfand

Latinx

This Week in HIV Research: Mitigating an ICE-y Reception

HIV ramifications of the Trump administration’s anti-immigration efforts; HIV in plasma vs. rectal tissue; how HCV treatment affects HIV/HCV coinfection; HPV vaccination efficacy among women with HIV.

This Week in HIV Research: A Yawning Racial Gap in U.S. Testing

HIV testing disparities among black MSM in the Southern U.S.; reasons for non-adherence in a vaginal HIV prevention ring trial; the importance of PrEP despite successful HIV treatment; inaccurate antiretroviral usage rates in Africa.

This Week in HIV Research: At-Home PrEP Care Advances

Fewer health care visits for PrEP recipients; sexual behavior in the U=U era; HIV and bone issues in women; how Medicaid enrollment gaps affect HIV treatment success.

This Week in HIV Research: Key Measures of Success Lag in the U.S. South

Lower CD4, higher viral load in the U.S. South; HIV testing among U.S. heterosexuals; heightened seroconversion risk around childbirth; predicting success for long-acting, injectable PrEP.

Bone

This Week in HIV Research: Not-So-Routine Testing

Missed chances for HIV testing; depressive symptoms associated with detectable HIV viral load; perceived HIV discrimination declines overall; zoledronic acid beats TDF switching for bone mass improvement.

This Week in HIV Research: Missed Opportunities to Close the Gap

Missed opportunities to prescribe PrEP to at-risk people; long-term viral suppression reduces cancer risk; sexual health clinics and linkage to care; neurocognitive benefits of low-dose hydrocortisone therapy for women.

Colds and Influenza

This Week in HIV Research: Self-Testing Passes a Big Test

HIV self-testing vs. professional HIV testing; the most effective influenza vaccine strategies for people with HIV; how age can affect flu vaccine efficacy; early HIV treatment and CD4:CD8 ratio normalization.

Is the World Ready for Long-Acting HIV Treatment?

How can science improve on its own miracle? This is the conundrum at the heart of an ongoing conversation in HIV medicine over the future of long-acting antiretroviral therapy, or LA-ART. The promise of LA-ART lies in the freedom it can potentially offe...

This Week in HIV Research: Monday, Wednesday, Treatment Days

Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.

People Who Use Drugs

This Week in HIV Research: Where Support Is Lacking, the Virus Can Spread

Housing, social support, and HIV transmissibility among people who use drugs; concerning hepatitis C incidence trends in France; frailty among people aging with HIV; untreated HIV and brain atrophy.